Review Article

Inflammasome in Intestinal Inflammation and Cancer

Tiago Nunes¹ and Heitor S. de Souza²

¹ Biofunctionality Unit, ZIEL Research Center for Nutrition and Food Sciences, Technical University of Munich, 85354 Freising-Weißenstephan, Germany
² Serviço de Gastroenterologia & Laboratório Multidisciplinar de Pesquisa, Hospital Universitário, Universidade Federal do Rio de Janeiro, 21941-913 Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Heitor S. de Souza; heitor.souza@gmail.com

Received 22 January 2013; Accepted 7 March 2013

Academic Editor: Amado Salvador Peña

Copyright © 2013 T. Nunes and H. S. de Souza. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The activation of specific cytosolic pathogen recognition receptors, the nucleotide-binding-oligomerization-domain- (NOD-) like receptors (NLRs), leads to the assembly of the inflammasome, a multimeric complex platform that activates caspase-1. The caspase-1 pathway leads to the upregulation of important cytokines from the interleukin (IL)-1 family, IL-1β, and IL-18, with subsequent activation of the innate immune response. In this review, we discuss the molecular structure, the mechanisms behind the inflammasome activation, and its possible role in the pathogenesis of inflammatory bowel diseases and intestinal cancer. Here, we show that the available data points towards the importance of the inflammasome in the innate intestinal immune response, being the complex involved in the maintenance of intestinal homeostasis, correct intestinal barrier function and efficient elimination of invading pathogens.

1. Introduction

In the human gut, trillions of bacteria interact with the host’s systemic immune system in a complex balance between immune activation and tolerance [1]. Pathogen recognition receptors (PRRs) have been shown to play an important role in the differentiation between commensal and pathogenic bacteria [2]. The detection of pathogen molecules collectively known as pathogen-associated molecular patterns (PAMPs) by PRRs activates the innate immune system, being involved in infection recognition and its consequent inflammatory response [2, 3]. The activation of PRRs can lead to enhanced production of proinflammatory cytokines with a wide range of systemic and local effects. Among them, interleukin (IL)-1β has been shown to be secreted in high amounts by colonic monocytes from patients with active inflammatory bowel disease (IBD), and intestinal levels are consistently correlated with disease activity suggesting an important role of this cytokine in intestinal inflammation [4]. In addition, IL-1 has also been implicated in the promotion of angiogenesis, tumor growth, and metastasis in experimental cancer models, being associated with more aggressive tumor biology [5, 6].

Generation of IL-1β requires the activity of caspase-1, but the mechanism involved in the activation of proinflammatory caspases remained to be established until 2002. In that year, the group of the late Jürg Tschopp reported the identification of the inflammasome, a multimeric molecular platform which triggers the activation of inflammatory caspases and processes pro-IL-1β [13]. Inflammasomes are cytosolic multiprotein complexes activated by specific PRRs which are involved in infection recognition and inflammation [13–17]. The structure of the inflammasome is assembled by intracellular nucleotide-binding-oligomerization-domain- (NOD-) like receptors (NLRs) to initiate innate immune responses against invading pathogens activating caspase-1 [15]. The subsequent activation of caspase-1 leads to enhanced expression of IL-1β and IL-18, recruitment and activation of immune cells, and triggering of pyroptosis, a caspase-1-dependent inflammatory form of cell death [14, 18–21].

The importance of the inflammasome and the cell death programming associated with microbial invasion is to restrict pathogen growth and to activate and recruit immune cells to mediate host defense. As the activation of the inflammasome and the caspase-1 pathway leads to enhanced production of
cytokines known to be upregulated in IBD and cancer, the role of this pathway in intestinal inflammation and colonic neoplasia has been the subject of intense research in recent years.

2. The Inflammasome

Inflammasomes are composed of multiprotein cytosolic complexes that gather to activate caspase-1 [13]. These multimeric platforms are found in a wide range of cell types including macrophages, dendritic cells, adipocytes, keratinocytes, and epithelial cells [22–28]. These complexes are activated either by NLR proteins NLRP1, NLRP3, NLRC4, NLRP6, and NAIP5 or by the DNA-sensing complex of AIM2, a member of the interferon-inducible HIN-200 protein family. Activation of these receptors by certain PAMPs leads to their oligomerization and subsequent interaction with the adaptor protein ASC and the CARD domain of caspase-1. ASC, as well, presents a CARD domain that works together with the CARD domain of procaspase-1 [15]. Inflammasome-activated caspase-1 is then used for activation of the proinflammatory cytokines IL-1β and IL-18, both belonging to the IL-1 family. These inflammatory cytokines enhance antimicrobial functions of phagosomes and promote protection against intracellular pathogens [16] (Figure 1).

3. Inflammasome and Inflammatory Bowel Disease

3.1. The Association between the Inflammasome and Inflammatory Bowel Diseases. Crohn’s disease (CD) and ulcerative colitis (UC) are chronic immune-mediated inflammatory diseases of the gastrointestinal tract that result from a dysregulated mucosal immune response to bacterial antigens in the gut lumen of a genetically susceptible host [29, 30]. In the gut-microbiota interplay related to IBD pathogenesis, several previous findings point towards the potential role of the inflammasome in the development of chronic intestinal inflammation. The first evidence refers to the upregulation of inflammatory cytokines IL-1β and IL-18 in active IBD, and the discovery of IL-18 gene polymorphisms associated with CD [31–33]. The second is the presence of a dysregulated IL-1β production linked to CD and the association between the NLRP3 inflammasome and three rare autoinflammatory chronic disorders treated with Canakinumab, a human monoclonal antibody targeted at IL-1β [22, 31, 34, 35]. The third, and perhaps the most important evidence, is the association between the NLRP3 gene and CD in candidate-gene approach studies.

Genome-wide association studies (GWAS) have tried to dissect the inherited element of IBD, identifying more than 70 CD and 40 UC susceptibility loci [36, 37]. These studies, however, do not explain the majority of the heritability related to IBD [38]. One interesting genomic region not associated with IBD in GWAS, but pointed out in candidate-gene approach studies and gene expression analysis data, is the NLRP3 gene which encodes the NLRP3 or cryopyrin protein [39–41]. This protein is part of the NLRP3-inflammasome, and it has a pivotal role in the pathogenesis of other chronic inflammatory disorders as pseudogout, gout, and familial Mediterranean fever [42–44]. As a result of the genetic link between NLRP3 and CD, the NLRP3 inflammasome is the most studied caspase-1 inducer multimeric platform in the field of chronic intestinal inflammation.

In two independent candidate-gene studies, the NLRP3 gene was associated with CD [39, 40], but there was no association in a posterior large study from the UK [45]. Interestingly, the first study conducted by Villani and coworkers also performed functional assays to evaluate the impact of these polymorphisms in NLRP3 expression and IL-1β production [39]. In this regard, NLRP3 SNPs were associated with lower levels of NLRP3 mRNA expression in a loss-of-function fashion with homozygosis for the risk allele being associated with the lowest level of NLRP3 expression in peripheral blood cells and monocytes. In addition, they observed an association between lower IL-1β levels and the risk NLRP3 allele in cultured monocytes in the presence or absence of lipopolysaccharide. In both cases, homozygosis for the risk allele was associated with the lowest level of IL-1β. Even though significantly higher IL-1β levels were found in the ulcerated intestinal mucosa from human CD samples...
than in healthy controls, it was postulated that a dysregulated IL-1β production might play a role in CD pathogenesis for patients bearing these SNPs.

The second study identifying an association between polymorphisms in the NLRP3 and CD included 498 cases and 794 controls, reporting that variants of NLRP3 conferred susceptibility to CD in Swedish male individuals [40]. Even though an NLRP3 genetic susceptibility was found in this population, careful analysis of the results show that, differently from the study by Villani and coworkers, the NLRP3 SNP associated with CD was a gain-of-function polymorphism, possibly promoting the production of mature IL-1β with subsequent induction of caspase-1 activity. The authors postulate that patients with this specific NLRP3 polymorphism might present an increased susceptibility to CD as a result of an increased IL-1β production and not due to a dysregulation of the pathway. In addition, the risk for developing CD in this study was exclusively associated with male patients bearing variant alleles in both NLRP3 and CARD8 genes. A third study evaluating the association between NLRP3 polymorphisms and IBD added more controversy to the topic. Lewis and coworkers raised questions about the previously reported association between CD and the NLRP3 locus supported by negative results based on control allele frequency data from large GWA studies [45].

3.2. Inflammasome Activation in the Gut. Even though the role of the NLRP3 inflammasome in IBD is still a matter of debate, the mechanisms behind its function started to be recently unveiled. NLRP3 can be triggered by bacterial constituents, synthetic purine-like compounds, endogenous urate crystals, and exogenous adenosine triphosphate (ATP) [46–48]. Of note, it was postulated that the passage of bacterial molecules into the host cytosol leading to NLRP3 inflammasome activation can be mediated by pannexin-1 and P2X7 receptor [49]. Pannexin-1 constitutes a transmembrane hemichannel that associates with P2X7 receptor, a member of the ATP-activated P2X purinergic receptors family, permeable to monovalent cations and anions, and capable of inducing the opening of a larger pore permeable to hydrophilic macromolecules [50]. In particular, the P2X7 receptors act as danger sensors in immune cells and have been implicated in different biological functions, including apoptosis and the production and release of proinflammatory cytokines [51].

In this regard, investigators have demonstrated that the cytosolic recognition of bacterial molecules resulting in the NLRP3 inflammasome activation is mediated by pannexin-1 activation [52]. These results seem to indicate that NLRP3 would function downstream of pannexin-L/P2X7 receptor in response to bacterial components to regulate caspase-1 activation (Figure 1). Furthermore, the expression and site-specific modulation of P2X7 receptors was demonstrated on epithelial and immune cells of the gut, supporting the suggestion of purinergic signaling as an additional component of the innate immune circuits involved in the control of inflammation and cell fate in the gut and gut-associated lymphoid tissues [53]. In addition, in intestinal epithelial cells, the expression of P2X7 receptors was also found to be upregulated by interferon-gamma, a proinflammatory cytokine and a signature molecule of the Th-1 type of immune response [54]. Moreover, ATP was shown to induce apoptosis and autophagy in human epithelial cells, possibly via reactive oxygen species production, through activation of the P2X7 receptor [55]. Taken together, these findings appear to implicate P2X7 receptors associated with pannexin-1 and the consequent NLRP3 inflammasome activation in the pathogenesis of diseases based on the dysregulation of the immune response such as IBD.

3.3. Inflammasome and Intestinal Inflammation in Animal Models. As the main downstream impact of the activation of the inflammasome is the upregulation of IL-18 and IL-1β, the knockout of these two important inflammatory cytokines as well as of other upstream regulators is pivotal to fully understand the role of the inflammasome in intestinal inflammation. Therefore, genetically modified mice lacking IL-18, IL-18 receptor (IL-18R), IL-1 receptor (IL-1R), NLRP3, NLRP6, ASC, and caspase-1 were constructed. In general, the susceptibility of these animals to intestinal inflammation was tested using the dextran sulphate sodium (DSS) experimental colitis model.

In the context of DSS colitis models, the role of IL-18 and IL-1β is still a matter of debate. More recently, it has been shown that IL-18 and IL-18R knockout mice develop more severe inflammation compared to wild-type, which is not true for IL-1R knockout mice [56, 57]. In an infection mouse model with C. rodentium, however, IL-1R knockout was shown to present increase mortality with severe colitis characterized by intramural colonic bleeding and intestinal damage following infection [57]. Consistent with these findings, most recent studies present clear data that mice lacking NLRP3 are more susceptible to develop colitis [26, 58–60] and ASC and caspase-1-deficient mice present enhanced susceptibility to DSS-induced inflammation [61].

However, other studies have shown exactly the opposite—that transgenic or pharmacological blockage of IL-1β converting enzyme (ICE) or IL-18 ameliorate DSS colitis [62–65]. In keeping with these results, Bauer and coworkers reported decreased sensitivity to DSS in NLRP3 deficient mice [66]. In that study, IL-1β secretion was abrogated in macrophages lacking NLRP3, ASC, or caspase-1 confirming that DSS activates caspase-1 via the NLRP3 inflammasome. After administration of DSS, NLRP3 knockout mice developed less severe colitis than wild-type mice and produced lower levels of proinflammatory cytokines in colonic tissue. In addition, pharmacological inhibition of caspase-1 with pralnacasan achieved a level of mucosal protection equivalent to NLRP3 deficiency. More recently, this protective role of NLRP3 against DSS colitis was also demonstrated by yet another independent group [67]. In any case, regardless of the still debated role of the NLRP3 inflammasome in DSS colitis, it has been shown that NLRP3, ASC, and caspase-1 deficient mice do not develop colitis without DSS treatment, implying that isolated inflammasome impairment does not result in spontaneous intestinal inflammation [61].
Another inflammasome, NLRP6 [68], has been associated with IBD [11, 12, 67]. Consistent with the presumed role for NLRP6 in gut inflammation signaling, Chen and coworkers have shown that mice lacking NLRP6 present decreased levels of serum IL-18 after DSS treatment [11]. These mice deficient in NLRP6 develop a colitis phenotype, and this is transmissible to cohoused wild-type mice, both early in postnatal life and during adulthood [67]. Upon injury, NLRP6 deficiency deregulates regeneration of the colonic mucosa and epithelial proliferation and migration. Consistently, an analysis on a whole-genome expression profiling revealed a link between NLRP6 and self-renewal of the epithelium [12]. The inability of mice lacking NLRP6 to repair damaged epithelium as efficiently as WT mice resulted in extended increase in epithelial proliferative activity [11].

Recently, the role of the inflammasome in gut-related infection and sepsis has also been addressed. For this purpose, it has been shown that mice treated with large-spectrum antibiotics before DSS intervention show symptoms of sepsis, not colitis, due to translocation of a pathogenic strain of E. coli [69]. This particular model is very significant due to its resemblance to the common clinical scenario in which patients undergoing antibiotic and gut-damaging cytotoxic treatments develop septicemia. In this antibiotics-DSS model, mice lacking NAIP5-NLRC4 presented highly attenuated disease progression when compared to controls. Similarly, caspase 1 and IL-1β deficient animals were protected from E. coli systemic inflammatory response showing that NAIP5-NLRC4 inflammasome signaling through IL-1β is important for the development of gut-related sepsis [69]. Locally, NLRC4-dependent IL-1β production by intestinal phagocytes represents a specific response discriminating pathogenic from commensal bacteria and contributes to host defense in the intestine [70]. Upon infection with pathogenic bacteria, intestinal phagocytes produce mature IL-1β through the NLRC4 inflammasome and mice deficient in NLRC4 or IL-1β receptor are highly susceptible to intestinal infection [70, 71]. It seems, however, that the inflammasome does not only signal through IL-1β or IL-18 in systemic inflammatory responses [72]. It has been shown that systemic inflammasome activation by flagellin leads to loss of vascular fluid into the intestine and peritoneal cavity and death in mice, and this outcome depends on NAIP5, NLRC4, and caspase-1 signaling, but is independent of IL-1β or IL-18 [72]. Instead, flagellin–related inflammasome activation results in a pathological release of signaling lipids, including prostaglandins and leukotrienes that rapidly initiate inflammation and vascular fluid loss.

4. Inflammasome and Colorectal Cancer

4.1. Colitis-Associated Tumorigenesis. The role of the inflammasome in cancer physiopathology is complex as it can either lead to inflammasome-dependent carcinogenic inflammation or play a role in the process of eliminating malignant precursors through programmed cell death [73]. Not only the product of the inflammasome activation, caspase-1, is associated with inflammation and carcinogenesis, but also it can stimulate immune responses against tumoral cells. In colonic tissue, the role of the inflammasome in colorectal cancer tumorigenesis was mainly explored using the azoxymethane (AOM) DSS model in which administration of DSS after initiation with a low dose of AOM exerts a powerful tumor-promoting inflammatory activity in colon in mice [74]. Using this inflammation-driven tumorigenesis model draws a parallel to the carcinogenic process that takes place in IBD-related intestinal neoplasia. In these models, it has been shown that the absence of inflammasome-related interleukins, mainly IL-18, can greatly impact carcinogenesis and tumor progression. IL-18-deficient mice, for instance, have increased inflammation and tumor development in a colitis-associated colon cancer model [8]. It seems, however, that IL-18 can also influence epithelial growth by regulating the production of additional interleukins. In this regard, activation of NLRP3 or NLRP6 inflammasomes leads to IL-18-dependent downregulation of IL-22 blocking protein (IL-22bp) and higher expression of IL-22. This IL-22-IL-22bp axis was shown to critically regulate intestinal tissue repair and tumorigenesis in the colon [75]. The main studies evaluating the role of the inflammasome in colitis-associated cancer using the AOM/DSS model are summarized in Table 1.

Mice lacking NLRP3 were shown to be more susceptible to tumorigenesis in the AOM-DSS model in some studies [7, 9], but not in others [10]. In studies that demonstrated a positive association, NLRP3 deficient mice presented more inflammation and higher tumor burden compared to controls. In these NLRP3 knockouts, colonic IL-18 levels were shown to be lower than those of controls. It was postulated, therefore, that IL-18 might be associated with colon protection against tumorigenesis. In this regard, knockout mice for IL-18 treated with AOM/DSS contained significantly more tumors than controls [7, 8]. Importantly, recombiant IL-18 was successfully used as rescue, being able to reverse disease progression perhaps through induction of IFN-γ and its antitumor signaling involving activation of the transcription factor STAT1 [7]. Of note, IL-18 uses MyD88 as a downstream signal transduction effector and MyD88 signaling has been shown to have a protective role in the development of AOM/DSS colitis [8]. It has been proposed that the increased susceptibility of IL-18 deficient mice to colitis and cancer in the AOM/DSS model may be partially dependent on MyD88-related mechanisms, although IL-18 deficient mice present a milder phenotype compared with Myd88 knockout mice (less tumorigenesis) implying that other MyD88-related pathways might act with IL-18 to minimize carcinogenesis [8].

In the negative study, there were no differences in tumor formation between NLRP3 deficient mice and controls after challenge with AOM-DSS [10]. In contrast, another inflammasome, NLRC4, was found to be associated with tumorigenesis in this model. In this regard, NLRC4 knockout mice had significantly increased tumor numbers and tumor load compared to wild-type animals, though no differences in inflammation severity were noted. Since NLRC4 is associated with p53-dependent apoptosis, it may provide a link to the increased tumorigenesis observed in caspase-1 deficient mice noted by three independent groups [7, 9, 10]. Caspase-1 has been shown to be associated with the regulation of
colonic epithelial cell proliferation and apoptosis and not only inflammation per se. As a result, caspase-1 deficient mice show increased colonic epithelial cell proliferation in early stages of tumor formation and reduced apoptosis in advanced tumors [10]. Hu and colleagues studied caspase-1 mRNA expression levels in normal colon tissue and colon tumors from WT mice observing a significant reduction in caspase-1 mRNA expression levels in tumors compared to normal colon tissue, suggesting that lack of caspase-1 may play a role in tumor progression [10]. Similarly to caspase-1 deficient mice, NLRC4 knockout mice features significantly enhanced proliferation in both steady state and the early phase of inflammation-induced tumor formation [10].

Another inflammasome, NLRP6, was also found to play a role in AOM-DSS tumorigenesis [11, 12]. In this regard, NLRP6-deficient mice developed significantly more tumors compared to wildtype mice after chemical induction. The increase in tumors in these mice correlated with higher levels of intestinal epithelial proliferation, hyperplasia, and increase in tumors in these mice correlated with higher levels of intestinal epithelial proliferation, hyperplasia, and increased colonic epithelial cell proliferation in ApcMin mice and controls treated with the DSS-AOM regimen [12]. Within the set of 1,884 genes that were differentially expressed in NLRP6 deficient mice, a significant overrepresentation of paracrine actors of the p53 Wnt and Notch signaling pathways was observed, supporting the role of NLRP6 in regulation of intestinal crypt cell proliferation. Notably, the microarray analysis clearly revealed an overexpression of Wnt-signaling pathway genes in tumor resection specimens of NLRP6 deficient mice, particularly the proto-oncogene Mycl1.

4.2. The Inflammasome in the ApcMin Model. In mice derived from animals treated with ethylnitrosourea, a mutation was identified that predisposed to the development of spontaneous intestinal cancer [76]. This mutation was later found to be located in the APC gene, the mouse homologue of the human APC gene responsible for human familial adenomatous polyposis [77]. The development of the APC deficient mice was one of the first spontaneous genetic animal models for bowel cancer [78]. In this model, affected mice develop multiple adenomas throughout the entire intestinal tract at an early age. It has been shown that innate immune signaling has an important role in the intestinal tumorigenesis in this model. In this regard, Rakoff-Nahoum and Medzhitov have shown that MyD88-dependent signaling controls the expression of several modifier genes of intestinal tumorigenesis in ApcMin mice [79]. ApcMin mice that are also deficient in MyD88 have decreased number of polyps which are smaller in size than those in age-matched ApcMin mice. In the inflammasome field, there were attempts to evaluate the potential impact of caspase-1 signaling in the development of tumors in ApcMin mice with disappoints results as the crossbreeding between ApcMin and caspase-1 deficient mice does not impact the phenotype [80].

5. Conclusion

In summary, the activation of specific NLR inflammasomes was shown to be triggered by microbial molecules, whereas
defects in NLRs determine innate immune system abnormalities and changes in the intestinal microbiota. In particular, intestinal dysbiosis has been consistently linked to intestinal inflammation through defects of NLR family members. In conjunction, these data highlight the importance of the inflammasome in the innate intestinal immune response and the maintenance of intestinal homeostasis, with fundamental influence on barrier function and the efficient elimination of invading microorganisms. Therefore, the abnormal activation of the inflammasome, converging signals from the internal and external milieu, sensing diverse stressful and microbial elements, appears to position inflammasome as a critical mechanistic link in the context of chronic inflammatory disorders involving the gut.

References

[1] I. Sekirov, S. L. Russell, L. Caetano M Antunes, and B. B. Finlay, “Gut microbiota in health and disease,” Physiological Reviews, vol. 90, no. 3, pp. 859–904, 2010.

[2] J. M. Wells, O. Rossia, M. Meijerkink, and P. Van Baaren, “Epithelial crosstalk at the microbiota-mucosal interface,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, supplement 1, pp. 4607–4614, 2011.

[3] L. Franchi and G. Nunez, “Immunology. Orchestrating inflammasomes,” Science, vol. 337, no. 6100, pp. 1299–1300, 2012.

[4] M. Coccia, O. I. Harrison, C. Schiering et al., “IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+(+) Th17 cells,” The Journal of Experimental Medicine, vol. 209, no. 9, pp. 1595–1609, 2012.

[5] D. M. Elaraj, D. M. Weinreich, S. Varghese et al., “The role of interleukin 1 in growth and metastasis of human cancer xenografts,” Clinical Cancer Research, vol. 12, no. 4, pp. 1088–1096, 2006.

[6] A. M. Lewis, S. Varghese, H. Xu, and H. R. Alexander, “Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment,” Journal of Translational Medicine, vol. 4, article 48, 2006.

[7] M. H. Zaki, P. Vogel, M. Body-Malapel, M. Lamkanfi, and T. D. Kanneganti, “IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation,” Journal of Immunology, vol. 185, no. 8, pp. 4912–4920, 2010.

[8] R. Salcedo, A. Worschech, M. Cardone et al., “MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18,” Journal of Experimental Medicine, vol. 207, no. 8, pp. 1625–1636, 2010.

[9] I. C. Allen, E. M. Tekippe, R. M. T. Woodford et al., “The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer,” Journal of Experimental Medicine, vol. 207, no. 5, pp. 1045–1056, 2010.

[10] B. Hu, E. Elinav, S. Huber et al., “Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLR4C4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 50, pp. 21635–21640, 2010.

[11] G. Y. Chen, M. Liu, F. Wang, J. Bertin, and G. Núñez, “A functional role for Nlrp6 in intestinal inflammation and tumorigenesis,” Journal of Immunology, vol. 186, no. 12, pp. 7187–7194, 2011.
[28] D. Lissner and B. Siegmund, “The multifaceted role of the inflammasome in inflammatory bowel diseases,” *The Scientific World Journal*, vol. 11, pp. 1536–1547, 2011.

[29] D. K. Podolsky, “Inflammatory bowel disease,” *New England Journal of Medicine*, vol. 347, no. 6, pp. 417–429, 2002.

[30] C. Fiocchi, “IBD: advances in pathogenesis, complications, diagnosis, and therapy,” *Current Opinion in Gastroenterology*, vol. 28, no. 4, pp. 297–300, 2012.

[31] J. Li, T. Moran, E. Swanson et al., “Regulation of IL-8 and IL-1β expression in Crohn’s disease associated NOD2/CARD15 mutations,” *Human Molecular Genetics*, vol. 13, no. 16, pp. 1715–1725, 2004.

[32] K. Tamura, Y. Fukuda, H. Sashio et al., “IL18 polymorphism is associated with an increased risk of Crohn’s disease,” *Journal of Gastroenterology*, vol. 37, supplement 14, pp. 111–116, 2002.

[33] A. Zhernakova, E. M. Festen, L. Franke et al., “Genetic association of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP,” *American Journal of Human Genetics*, vol. 82, no. 5, pp. 1202–1210, 2008.

[34] S. Mariathasan and D. M. Monack, “Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation,” *Nature Reviews Immunology*, vol. 7, no. 1, pp. 31–40, 2007.

[35] C. A. Dinarello, A. Simon, and J. W. van der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” *Nature Reviews Drug Discovery*, vol. 11, no. 8, pp. 633–652, 2012.

[36] A. Franke, D. P. B. McGovern, J. C. Barrett et al., “Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci,” *Nature Genetics*, vol. 42, no. 12, pp. 1118–1125, 2010.

[37] C. A. Anderson, G. Boucher, C. W. Lees et al., “Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47,” *Nature Genetics*, vol. 43, no. 3, pp. 246–252, 2011.

[38] G. Gibson, “Hints of hidden heritability in GWAS,” *Nature Genetics*, vol. 42, no. 7, pp. 558–560, 2010.

[39] A. C. Villani, M. Lemire, G. Fortin et al., “Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility,” *Nature Genetics*, vol. 41, no. 1, pp. 71–76, 2009.

[40] I. Schulz, D. Verma, J. Halfvarsson et al., “Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to crohn’s disease in swedish men,” *American Journal of Gastroenterology*, vol. 104, no. 5, pp. 1180–1188, 2009.

[41] G. V. Glinsky, “SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways,” *Cell Cycle*, vol. 7, no. 22, pp. 3564–3576, 2008.

[42] S. R. Kingsbury, P. G. Conaghan, and M. F. McDermott, “The role of the NLRP3 inflammasome in gout,” *Journal of Inflammation Research*, vol. 4, no. 1, pp. 39–49, 2011.

[43] F. A. Amaral, V. V. Costa, L. D. Tavares et al., “NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout,” *Arthritis & Rheumatism*, vol. 64, no. 2, pp. 474–484, 2012.

[44] V. U. Ozkurede and L. Franchi, “Immunology in clinic review series, focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes,” *Clinical & Experimental Immunology*, vol. 167, no. 3, pp. 382–390, 2012.

[45] G. J. Lewis, D. C. O. Massey, H. Zhang et al., “Genetic association between NLRP3 variants and Crohn’s disease does not replicate in a large UK panel,” *Inflammatory Bowel Diseases*, vol. 17, no. 6, pp. 1387–1391, 2011.

[46] T. D. Kanneganti, M. Body-Malapel, A. Amer et al., “Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA,” *Journal of Biological Chemistry*, vol. 281, no. 48, pp. 36560–36568, 2006.

[47] T. D. Kanneganti, N. Özören, M. Body-Malapel et al., “Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3,” *Nature*, vol. 440, no. 7081, pp. 233–236, 2006.

[48] S. Mariathasan, D. S. Weiss, K. Newton et al., “Cryopyrin activates the inflammasome in response to toxins and ATP,” *Nature*, vol. 440, no. 7081, pp. 228–232, 2006.

[49] P. Pelegrin and A. Surprenant, “Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor,” *EMBO Journal*, vol. 25, no. 21, pp. 5071–5082, 2006.

[50] R. A. North, “Molecular physiology of P2X receptors,” *Physiological Reviews*, vol. 82, no. 4, pp. 1013–1067, 2002.

[51] L. Chen and C. F. Brosnan, “Regulation of immune response by P2X7 receptor,” *Critical Reviews in Immunology*, vol. 26, no. 6, pp. 499–513, 2006.

[52] T. D. Kanneganti, M. Lamkanfi, and G. Núñez, “Intracellular NOD-like receptors in host defense and disease,” *Immunity*, vol. 27, no. 4, pp. 549–559, 2007.

[53] N. de Campos, C. Marques-da-Silva, G. Corrêa, M. T. Castelo-Branco, H. S. de Souza, and R. Coutinho-Silva, “Characterizing the presence and sensitivity of the P2X7 receptor in different compartments of the gut,” *Journal of Innate Immunity*, vol. 4, pp. 529–541, 2012.

[54] L. Welte-Stahl, C. M. da Silva, J. Schachter et al., “Expression of purinergic receptors and modulation of P2X7 function by the inflammatory cytokine IFNγ in human epithelial cells,” *Biochimica et Biophysica Acta*, vol. 1788, no. 5, pp. 1167–1187, 2009.

[55] C. O. Souza, G. F. Santoro, V. R. Figliuolo et al., “Extracellular ATP induces cell death in human intestinal epithelial cells,” *Biochimica et Biophysica Acta*, vol. 1820, no. 12, pp. 1867–1878, 2012.

[56] H. Takagi, T. Kanai, A. Okazawa et al., “Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice,” *Scandinavian Journal of Gastroenterology*, vol. 38, no. 8, pp. 837–844, 2003.

[57] S. L. Lebeis, K. R. Powell, D. Merlin, M. A. Sherman, and D. Kalman, “Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen citrobacter rodentium,” *Infection and Immunity*, vol. 7, no. 2, pp. 604–614, 2009.

[58] M. H. Zaki, M. Lamkanfi, and T. D. Kanneganti, “The Nlrp3 inflammasome: contributions to intestinal homeostasis,” *Trends in Immunology*, vol. 32, no. 4, pp. 171–179, 2011.

[59] I. C. Allen, J. E. Wilson, M. Schneider et al., “NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling,” *Immunity*, vol. 36, no. 5, pp. 742–754, 2012.

[60] S. A. Hirota, J. Ng, A. Lueng et al., “NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis,” *Inflammatory Bowel Diseases*, vol. 17, no. 6, pp. 1359–1372, 2011.

[61] J. Dupaul-Chicoine, G. Yeretsian, K. Doiron et al., “Control of intestinal homeostasis, Collins, and Collins-associated colorectal cancer by the inflammatory caspases,” *Immunity*, vol. 32, no. 3, pp. 367–378, 2010.
B. Siegmund, H. A. Lehr, G. Fantuzzi, and C. A. Dinarello, "IL-1β-converting enzyme (caspase-1) in intestinal inflammation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 23, pp. 13249–13254, 2001.

B. Siegmund, G. Fantuzzi, F. Rieder et al., "Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production," *American Journal of Physiology*, vol. 281, no. 4, pp. R1264–R1273, 2001.

T. Ishikura, T. Kanai, K. Uraushihara et al., "Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice," *Journal of Gastroenterology and Hepatology*, vol. 18, no. 8, pp. 960–969, 2003.

C. Bauer, F. Loher, M. Dauer et al., "The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-α mRNA expression," *Digestive Diseases and Sciences*, vol. 52, no. 7, pp. 1642–1652, 2007.

C. Bauer, P. Duewell, C. Mayer et al., "Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome," *Gut*, vol. 59, no. 9, pp. 1192–1199, 2010.

E. Elinav, T. Strowig, A. L. Kau et al., "NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis," *Cell*, vol. 145, no. 5, pp. 745–757, 2011.

J. M. Grenier, L. Wang, G. A. Manji et al., "Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-κB and caspase-1," *FEBS Letters*, vol. 530, no. 1–3, pp. 73–78, 2002.

J. S. Ayres, N. J. Trinidad, and R. E. Vance, "Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota," *Nature Medicine*, vol. 18, no. 5, pp. 799–806, 2012.

L. Franchi, N. Kamada, Y. Nakamura et al., "NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense," *Nature Medicine*, vol. 13, no. 5, pp. 449–456, 2012.

Z. Liu, M. H. Zaki, P. Vogel et al., "Role of inflammasomes in host defense against Citrobacter rodentium infection," *The Journal of Biological Chemistry*, vol. 287, no. 20, pp. 16955–16964, 2012.

J. von Moltke, N. J. Trinidad, M. Moayeri et al., "Rapid induction of inflammatory lipid mediators by the inflammasome in vivo," *Nature*, vol. 490, no. 7418, pp. 107–111, 2012.

L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer, "Inflammasomes in carcinogenesis and anticancer immune responses," *Nature Immunology*, vol. 13, no. 4, pp. 343–351, 2012.

T. Tanaka, H. Kohno, R. Suzuki, Y. Yamada, S. Sugie, and H. Mori, "A novel inflammation-related mouse colon carcinoma model induced by azoxymethane and dextran sodium sulfate," *Cancer Science*, vol. 94, no. 11, pp. 965–973, 2003.

S. Huber, N. Gagliani, L. A. Zeneewicz et al., "IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine," *Nature*, vol. 491, no. 7423, pp. 259–263, 2012.

A. R. Moser, H. C. Pitot, and W. F. Dove, "A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse," *Science*, vol. 247, no. 4940, pp. 322–324, 1990.

L. K. Su, K. W. Kinzler, B. Vogelstein et al., "Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene," *Science*, vol. 256, no. 5057, pp. 668–670, 1992.

M. Oshima, H. Oshima, K. Kitagawa, M. Kobayashi, C. Itakura, and M. Taketo, "Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 10, pp. 4482–4486, 1995.

S. Rakoff-Nahoum and R. Medzhitov, "Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88," *Science*, vol. 317, no. 5834, pp. 124–127, 2007.